Company: CI
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001739940-25-000037
Chunk: 73

Company: Cigna Group
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 73
---
 30, 2024(Shares in thousands, dollars in millions, except per share amounts)BasicEffect ofDilutionDilutedBasicEffect ofDilutionDilutedShareholders' net income$4,723 $4,723 $2,010 $2,010 Shares:Weighted average267,635 267,635 282,005 282,005 Common stock equivalents1,892 1,892 3,037 3,037 Total shares267,635 1,892 269,527 282,005 3,037 285,042 Earnings per share$17.65 $(0.13)$17.52 $7.13 $(0.08)$7.05 

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:Three Months Ended September 30,Nine Months Ended September 30,(In millions)2025202420252024Anti-dilutive options2.1 0.8 1.9 1.0 

The Company held approximately 137.4 million shares of common stock in treasury as of September 30, 2025, 128.7 million shares as of December 31, 2024 and 122.5 million shares as of September 30, 2024.

13

Note 7 – Debt

Short-Term and Long-Term Debt. During the nine months ended September 30, 2025, the Company redeemed at par its $700 million 5.685% senior notes that were due March 2026 and repaid $900 million 3.250% senior notes that matured in April 2025. For more information regarding our short-term and long-term debt, see Note 7 of the Company's 2024 Form 10-K.

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described below. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.PrincipalMaturity DateInterest RateNet ProceedsRedeemable Date(1)"Make Whole" Premium (2)$1,000 millionSeptember 15